Citius Oncology, Inc. (CTOR) — Cash Flow Quality Index
Citius Oncology, Inc. (CTOR) has a Cash Flow Quality Index of -1.44x as of June 2024. Operating cash flow of $-364.06K is below net income of $252.46K, suggesting accrual-heavy earnings not yet converted to cash. Also explore CTOR total asset value for the complete picture of this company's asset base.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Citius Oncology, Inc. Cash Flow Quality Index (2022–2023)
Historical Cash Flow Quality Index for Citius Oncology, Inc. across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check tangible equity quality of Citius Oncology, Inc. to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Citius Oncology, Inc. (2022–2023)
Year-by-year earnings quality comparison for Citius Oncology, Inc.. For live market cap and the full company financial profile, see market cap of Citius Oncology, Inc..
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2023 | -0.25x | $-601.30K | $2.42 Million | ▼ -97.3% |
| 2022 | -0.13x | $-47.97K | $380.81K | — |